Hausmann N, Stefani F H
Department of Ophthalmology, Landeskrankenhaus Feldkirch, Austria.
J Cancer Res Clin Oncol. 1991;117(1):4-5. doi: 10.1007/BF01613188.
According to recent data the incidence of second tumors in cured hereditary unilateral retinoblastoma patients is 20% within 10 years, 50% after 20 years and rises to 90% after 30 years. Nonhereditary unilateral retinoblastoma patients have not been regarded as susceptible for second nonocular tumors so far. A case is reported of such a patient having developed a second presacral retroperitoneal tumor after successful treatment of a nonhereditary unilateral retinoblastoma group V without intracranial extension or pulmonary metastases. Consequently all (hereditary and non-hereditary) retinoblastoma patients should receive at least quarterly intensive follow-up examinations after primary ophthalmologic treatment.
根据最近的数据，治愈的遗传性单侧视网膜母细胞瘤患者发生二次肿瘤的发生率在10年内为20%，20年后为50%，30年后升至90%。迄今为止，非遗传性单侧视网膜母细胞瘤患者尚未被视为易患非眼部二次肿瘤。本文报告了1例非遗传性单侧视网膜母细胞瘤Ⅴ组患者，在成功治疗且无颅内扩展或肺转移后，发生了骶前腹膜后二次肿瘤。因此，所有（遗传性和非遗传性）视网膜母细胞瘤患者在接受初次眼科治疗后，应至少每季度进行一次强化随访检查。
